Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (2407)	7/17/1999 3:37:00 PM
From: Walter Morton	Respond to of 2742

PAI-2 DNA Patent Cistron granted an exclusive sublicense to Biotech Australia Pty. Limited to make, use and sell PAI-2. "A much larger clinical trial involving 120 patients with chronic leg ulcers is now underway in Sydney, Melbourne, Canberra and Perth. "If large scale (Phase II) clinical trials confirm the effectiveness of the treatments the product could be on the market in four years, most probably in a gel form that is easy and convenient to use at home. "Health care costs worldwide associated with leg ulcers are estimated to be $1.5 billion a year. "Entering Phase II trials for the product represents a major advance for Biotech Australia towards developing and manufacturing human Pharmaceuticals," said Dr David Harrison Chief Executive Officer of the company." bioaust.com.au